| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | BIRC2 |
| Uniprot No | Q13490 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-618aa |
| 氨基酸序列 | MHKTASQRLF PGPSYQNIKS IMEDSTILSD WTNSNKQKMK YDFSCELYRM STYSTFPAGV PVSERSLARA GFYYTGVNDK VKCFCCGLML DNWKLGDSPI QKHKQLYPSC SFIQNLVSAS LGSTSKNTSP MRNSFAHSLS PTLEHSSLFS GSYSSLSPNP LNSRAVEDIS SSRTNPYSYA MSTEEARFLT YHMWPLTFLS PSELARAGFY YIGPGDRVAC FACGGKLSNW EPKDDAMSEH RRHFPNCPFL ENSLETLRFS ISNLSMQTHA ARMRTFMYWP SSVPVQPEQL ASAGFYYVGR NDDVKCFCCD GGLRCWESGD DPWVEHAKWF PRCEFLIRMK GQEFVDEIQG RYPHLLEQLL STSDTTGEEN ADPPIIHFGP GESSSEDAVM MNTPVVKSAL EMGFNRDLVK QTVQSKILTT GENYKTVNDI VSALLNAEDE KREEEKEKQA EEMASDDLSL IRKNRMALFQ QLTCVLPILD NLLKANVINK QEHDIIKQKT QIPLQARELI DTILVKGNAA ANIFKNCLKE IDSTLYKNLF VDKNMKYIPT EDVSGLSLEE QLRRLQEERT CKVCMDKEVS VVFIPCGHLV VCQECAPSLR KCPICRGIIK GTVRTFLS |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于BIRC2重组蛋白的3篇代表性文献及其摘要概括：
---
1. **文献名称**：*Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain*
**作者**：Wu, G. et al.
**摘要**：该研究解析了BIRC2(XIAP)的BIR结构域与促凋亡蛋白Smac/DIABLO的复合物晶体结构，利用重组BIRC2蛋白揭示了其通过BIR3结构域特异性结合Smac的分子机制，为凋亡调控提供了结构基础。
---
2. **文献名称**：*IAP antagonists induce autoubiquitination of c-IAPs, NF-κB activation, and TNFα-dependent apoptosis*
**作者**：Varfolomeev, E. et al.
**摘要**：通过重组BIRC2(c-IAP1)蛋白实验，证明IAP拮抗剂可诱导其自泛素化降解，激活NF-κB通路并促进肿瘤坏死因子(TNFα)依赖的细胞凋亡，阐明了c-IAP1在癌症治疗中的靶点作用。
---
3. **文献名称**：*The ubiquitin-mediated degradation of the epidermal growth factor receptor requires the binding of c-Cbl to a singular site of the E3 ligase c-IAP1*
**作者**：Yang, W. et al.
**摘要**：研究发现重组BIRC2(c-IAP1)蛋白作为E3泛素连接酶，通过结合c-Cbl促进表皮生长因子受体(EGFR)的泛素化降解，揭示了其在受体酪氨酸激酶信号调控中的新功能。
---
这些文献涵盖了BIRC2重组蛋白在结构生物学、凋亡信号通路及泛素化调控中的关键研究，可为进一步探索其功能提供参考。
BIRC2 (Baculoviral IAP Repeat-Containing Protein 2), also known as cIAP1. is a member of the inhibitor of apoptosis (IAP) family, which plays critical roles in regulating cell survival, apoptosis, and inflammatory signaling pathways. It is characterized by the presence of three baculoviral IAP repeat (BIR) domains that mediate protein-protein interactions, a ubiquitin-associated (UBA) domain involved in ubiquitin binding, and a RING finger domain conferring E3 ubiquitin ligase activity. BIRC2 functions primarily by inhibiting caspase activation, thereby suppressing apoptosis, and by modulating NF-κB signaling through ubiquitination-dependent mechanisms.
Recombinant BIRC2 protein is engineered through molecular cloning techniques, often expressed in bacterial or mammalian systems to ensure proper post-translational modifications. This purified protein is widely used in biochemical and cellular studies to investigate its interactions with caspases, SMAC/DIABLO (a pro-apoptotic protein that antagonizes IAPs), and components of the TNF receptor signaling complex. Researchers also employ recombinant BIRC2 to explore its role in cancer progression, as overexpression of BIRC2 is linked to tumor resistance to chemotherapy and apoptosis evasion. Additionally, it serves as a tool for developing therapeutic agents, such as SMAC mimetics, which aim to neutralize BIRC2’s anti-apoptotic activity in cancer cells.
Beyond oncology, BIRC2’s involvement in immune regulation and inflammatory diseases makes it a target for studying conditions like rheumatoid arthritis and neurodegenerative disorders. Its dual role in cell death and survival underscores its biological complexity, driving ongoing research to unravel context-specific mechanisms and therapeutic potentials. Recombinant BIRC2 thus remains a vital reagent for dissecting apoptotic pathways and designing precision therapies.
×
